Bessemer Group Inc. Sells 2,485 Shares of Repligen Corporation $RGEN

Bessemer Group Inc. cut its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 1.0% during the 2nd quarter, Holdings Channel reports. The fund owned 250,529 shares of the biotechnology company’s stock after selling 2,485 shares during the period. Bessemer Group Inc.’s holdings in Repligen were worth $31,159,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Twin Tree Management LP bought a new position in Repligen during the first quarter worth $29,000. Signaturefd LLC boosted its stake in Repligen by 65.3% during the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 128 shares in the last quarter. AlphaQuest LLC bought a new position in Repligen during the second quarter worth $104,000. GAMMA Investing LLC boosted its stake in Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 274 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new position in Repligen during the first quarter worth $132,000. 97.64% of the stock is owned by institutional investors.

Repligen Stock Down 3.1%

Repligen stock opened at $161.10 on Tuesday. The company has a current ratio of 8.59, a quick ratio of 7.32 and a debt-to-equity ratio of 0.26. The firm’s fifty day moving average price is $133.33 and its two-hundred day moving average price is $128.20. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The firm has a market capitalization of $9.06 billion, a price-to-earnings ratio of -644.37, a price-to-earnings-growth ratio of 3.68 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The firm had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same period in the previous year, the business earned $0.40 earnings per share. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. On average, equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Martin D. Madaus purchased 1,800 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the transaction, the director directly owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RGEN. HSBC began coverage on shares of Repligen in a research note on Wednesday, October 1st. They set a “buy” rating and a $150.00 target price on the stock. Evercore ISI raised their price objective on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Barclays raised their price objective on shares of Repligen from $150.00 to $160.00 and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Stephens raised shares of Repligen to an “overweight” rating and set a $160.00 price objective on the stock in a research note on Tuesday, July 22nd. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Repligen in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $169.62.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.